Last updated: June 29, 2026
Valeant v. PAR Pharmaceutical (1:18-cv-08221) Litigation Summary and Analysis: What Claims Were at Stake, What Happened Procedurally, and What It Means for Generic Entry
What is Valeant Pharmaceuticals North America LLC v. PAR Pharmaceutical, Inc. 1:18-cv-08221 about?
Core dispute: Valeant Pharmaceuticals North America LLC (Valeant) sued PAR Pharmaceutical, Inc. (PAR) in a Hatch-Waxman patent infringement case filed as Case No. 1:18-cv-08221 (U.S. District Court, Southern District of New York, per the docket prefix). The litigation is framed around Valeant’s patents covering a branded pharmaceutical product and PAR’s plan to market a generic or authorized product under Hatch-Waxman (Orange Book) Paragraph IV.
What this case typically means in practice: When a brand sues a generic under Hatch-Waxman, the lawsuit is tied to (1) Orange Book-listed patents, (2) the generic’s ANDA certification (often Paragraph IV), and (3) the statutory 30-month stay (if a required trigger occurred). The business impact is whether PAR could launch at-risk, enter via settlement/licensing, or be delayed by injunction or unresolved claims.
Which patents and products were litigated in Valeant v. PAR (1:18-cv-08221)?
No verifiable, docket-specific patent numbers, Orange Book identifiers, asserted claims, or product details were provided in the prompt. Without the complaint/Amended Complaint, infringement contentions, or final judgment/order text tied to 1:18-cv-08221, a complete litigation summary cannot be produced accurately.
What happened procedurally in the case (motions, rulings, settlements, dismissals)?
No docket events, hearing dates, court orders, Markman activity, summary judgment outcomes, settlement filings, or final disposition for 1:18-cv-08221 were provided in the prompt.
What is the litigation outcome and how does it affect generic launch timing for PAR?
A legally actionable analysis requires one of the following:
- final judgment (infringement, non-infringement, invalidity, unenforceability),
- dismissal status,
- any entry/injunction dates,
- settlement agreement timing and terms (including license scope and launch dates),
- or the 30-month stay trigger and any lifting event.
None of these facts were supplied in the prompt, so an outcome-based exclusivity and launch-risk analysis cannot be produced.
How strong were Valeant’s claims in Valeant v. PAR (1:18-cv-08221) based on court reasoning?
Evaluating “strength” requires at minimum:
- the claim construction results,
- the court’s infringement analysis,
- validity/obviousness/anticipation determinations,
- and any standards applied (e.g., obviousness frameworks, written description, enablement, indefiniteness findings).
No substantive rulings or opinion excerpts for 1:18-cv-08221 were provided in the prompt.
Did PAR assert counterclaims (invalidity, non-infringement), and what defenses were used?
A counterclaim/defense analysis needs the invalidity grounds and specific defenses asserted in PAR’s answer and invalidity contentions, plus any later amendments. Those details were not provided.
How does this case fit into Hatch-Waxman Paragraph IV litigation patterns and 30-month stay effects?
A Hatch-Waxman framework can be stated at a general level, but the question here is the case-specific effect on PAR’s launch window. Case-specific outcomes depend on:
- the filing date of the complaint and the Paragraph IV notice,
- whether the required “substantial question of patent infringement” standard applied,
- the date(s) of any district court decision and whether appealed,
- and whether settlement mooted the infringement dispute.
Those case dates and events were not provided.
What settlements or license terms were reached in Valeant v. PAR (1:18-cv-08221)?
No settlement document references, license start dates, royalty terms, covenants not to sue, field-of-use limits, carve-outs, or stipulated dismissal terms were provided.
What is the Orange Book status of the patents in suit, and which versions could be impacted?
Orange Book status requires:
- the NDA number,
- the listed patents by expiration,
- and whether the asserted patents are composition, formulation, method-of-use, or packaging/manufacturing.
None of those Orange Book identifiers were provided in the prompt.
Comparison: How does Valeant v. PAR (1:18-cv-08221) compare with other Valeant vs. generic cases?
A comparative litigation analysis requires at least:
- other Valeant matters involving similar dosage forms or patent families,
- their outcomes,
- and the relationship among patent portfolios.
No other case data was provided.
Key Takeaways
- Case identification alone (1:18-cv-08221) is insufficient to produce a correct litigation summary because patent numbers, asserted claims, procedural history, and final disposition were not provided.
- A useful business analysis for generic entry risk must rest on docket-specific facts (orders/judgments/settlement entries and Orange Book-linked patent details). Those facts are absent from the prompt.
FAQs
- What documents typically control a Hatch-Waxman litigation summary in a case like 1:18-cv-08221?
- How do Paragraph IV notices translate into the 30-month stay in district court?
- What evidence is usually decisive in pharma patent infringement suits at summary judgment?
- How do settlements typically alter launch timing and allowable product scope?
- What is the difference in litigation posture when the asserted patents are method-of-use versus composition?
References
No sources were cited because the prompt contained no docket-specific facts or verifiable documents to support citation-grade statements.
